| Neoepitopes as cancer immunotherapy targets: key challenges and opportunities CA Brennick, MM George, WL Corwin, PK Srivastava, H Ebrahimi-Nik Immunotherapy 9 (4), 361-371, 2017 | 79 | 2017 |
| Zinc induces dendritic cell tolerogenic phenotype and skews regulatory T cell–Th17 balance MM George, K Subramanian Vignesh, JA Landero Figueroa, JA Caruso, ... The Journal of Immunology 197 (5), 1864-1876, 2016 | 67 | 2016 |
| An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection CA Brennick, MM George, MM Moussa, AT Hagymasi, S Al Seesi, ... The Journal of clinical investigation 131 (3), 2021 | 28 | 2021 |
| Prediction of cancer neoepitopes needs new rules CA Brennick, MM George, PK Srivastava, SH Karandikar Seminars in Immunology 47, 101387, 2020 | 23 | 2020 |
| Transcription factor KLF2 in dendritic cells downregulates Th2 programming via the HIF-1α/Jagged2/Notch axis Y Xiong, JB Lingrel, M Wüthrich, BS Klein, NT Vasudevan, MK Jain, ... MBio 7 (3), 10.1128/mbio. 00436-16, 2016 | 21 | 2016 |
| Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine M Gigoux, MO Holmström, R Zappasodi, JJ Park, S Pourpe, CC Bozkus, ... Science translational medicine 14 (649), eaba4380, 2022 | 12 | 2022 |
| Unbiased identification of tumor rejection mediating neoepitopes PK Srivastava, II Mandoiu, CA Brennick, MM George, M Moussa US Patent 11,920,202, 2024 | 1 | 2024 |
| CD8+ T Cell–Dependent Antitumor Activity In Vivo of a Mass Spectrometry–Identified Neoepitope despite Undetectable CD8+ Immunogenicity In Vitro MA Gillig, CA Brennick, MM George, JL Balsbaugh, TV Shcheglova, ... The Journal of Immunology, 2023 | 1 | 2023 |
| APR-246 enhances tumor immunogenicity even in the absence of p53 D Venkatesh, J Michels, C Liu, S Budhu, MM George, L Abrahmsen, ... Cancer Research 82 (12_Supplement), 1291-1291, 2022 | 1 | 2022 |
| Modeling tumor immunoediting under immune selective pressure to inform neoantigen landscape dynamics for effective cancer vaccines MM George, J Lihm, H Choi, Y Elhanati, S Martis, M Luksza, ... Cancer Research 84 (6_Supplement), 4093-4093, 2024 | | 2024 |
| Gut microbiota mimics as a source of cross-reactive tumor rejection antigens V Panneton, M Gigoux, A Zebboudj, N Sadek, H Choi, LM Mangarin, ... Cancer Research 84 (6_Supplement), 4090-4090, 2024 | | 2024 |
| APR-246 increases tumor antigenicity independent of p53 J Michels, D Venkatesh, C Liu, S Budhu, H Zhong, MM George, D Thach, ... Life Science Alliance 7 (1), 2024 | | 2024 |
| 789 Immune checkpoint blockade augments cyclophosphamide induced anti-tumor immunity by expanding effector CD8+ T cell clones in a preclinical melanoma model MM George, L Hamadene, NJ Ceglia, Y Marouf, D Hirschhorn, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Immune modulation of the T cell repertoire in mice following immunotherapy and chemotherapy combination treatments Y Elhanati, MM George, H Choi, R Maniyar, L Hamadane, N Mohibullah, ... Cancer Research 83 (7_Supplement), 2282-2282, 2023 | | 2023 |
| Modeling tumor immunoediting coupled with T-cell repertoire dynamic J Lihm, H Choi, MM George, Y Elhanati, D Hoyos, M Luksza, T Merghoub, ... Cancer Research 83 (7_Supplement), 610-610, 2023 | | 2023 |
| CD8 T Cell− Dependent Antitumor Activity In Vivo of a Mass Spectrometry− Identified Neoepitope despite Undetectable CD8 Immunogenicity In Vitro MA Gillig, CA Brennick, MM George, JL Balsbaugh, TV Shcheglova, ... | | 2023 |
| 903 APR-246 induces an increase in tumor immunogenicity in a p53 independent manner D Venkatesh, J Michels, C Lu, S Budhu, M George, O Ouerfelli, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model MM George, AB Warner, L Hamadene, D Hirschhorn, AN Houghton, ... Cancer Research 82 (12_Supplement), 4167-4167, 2022 | | 2022 |
| 772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination M Gigoux, R Zappasodi, J Park, CC Bozkus, L Mangarin, D Redmond, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| Unbiased analysis of all possible neoepitopes of MC38-FABF tumor reveals a new universe of cancer neoepitopes with unexpected properties MM George, CA Brennick, MM Moussa, AT Hagymasi, SA Seesi, ... The Journal of Immunology 204 (1_Supplement), 239.18-239.18, 2020 | | 2020 |
